Craig C. Hofmeister, MD, MPH

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (187 ratings)

Role

Hematology Oncology
Specialty

Myeloma and Plasma Cell Disorders
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2006

Call 404-778-0519

Background

Craig C. Hofmeister, MD, MPH, is board certified in hematology and his practice focuses on plasma cell cancers including plasmacytomas, multiple myeloma, AL amyloidosis, smoldering myeloma and monoclonal gammopathies of clinical significance. He started practicing with Emory Healthcare in 2018. Dr. Hofmeister is a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.

Dr. Hofmeister earned his Medical Degree and his Master of Public Health in Clinical Investigation from The Ohio State University in Columbus, Ohio. He completed his internship and hematology fellowship at Loyola University.

Titles & Roles

Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, 2006
Loyola Univ. Medical Center
Fellowship, Hematology/Oncology, 2005
Loyola Univ. Medical Center
Residency, Internal Medicine, 2002
Loyola Univ. Medical Center
Medical Education, MD, 1999
Ohio State University College of Medicine

Board Certifications

Hematology
American Board of Internal Medicine, 2005
Internal Medicine
American Board of Internal Medicine, 2002

Research

Dr. Hofmeister's research focus is on early drug development and the use of large datasets to ask and answer pertinent questions as a translational informaticist.

View Current Clinical Trials


Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma Phase III Conditions Multiple Myeloma Location Winship Cancer Institute
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma Phase I Conditions Multiple Myeloma Location Winship Cancer Institute
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis Phase I Conditions AL Amyloidosis Location Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
Persistent opioid use is associated with a shorter myeloma survival. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer	K Sweiss, AMA Rodriguez, JG Quigley, L Sharp, K Kurzweil, JG Sweis, GS Calip, Z Hamilton, C Uzoka, E Ilo, E Wolf, D Rondelli, DW Sborov, P Patel, CC Hofmeister	04/11/2025
Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood	O Landgren, A Chari, YC Cohen, A Spencer, PM Voorhees, I Sandhu, MW Jenner, D Smith, M Cavo, NWCJ van de Donk, M Beksac, P Moreau, H Goldschmidt, D Vieyra, L Sha, L Li, E Rousseau, R Dennis, R Carson, CC Hofmeister	04/10/2025
Immune-aging is linked to clinical malignancy, racial ancestry and vaccine responses in myeloma. Blood advances	SV Potdar, S Kapadia, MI Azeem, R Radzievski, K Lakhani, NS Joseph, JL Kaufman, CC Hofmeister, VA Gupta, S Lonial, AK Nooka, KM Dhodapkar, MV Dhodapkar	02/05/2025
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects. Journal of hematology & oncology	AA Dona, T Tandoh, L Nigam, M Singer, E Caserta, M Murtadha, Y Zhu, M Moloudizargari, P Sharma, O Napolitano, J Winchester, A Chowdhury, A Pozhitkov, JF Sanchez, H Vahed, G Marcucci, M Coffey, G Nuovo, DW Sborov, F Pichiorri, CC Hofmeister	01/20/2025
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity. NPJ vaccines	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	10/27/2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood cancer journal	NS Joseph, JL Kaufman, VA Gupta, CC Hofmeister, MV Dhodapkar, LH Boise, SM DiCamillo, D Roberts, AK Nooka, S Lonial	09/13/2024
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood cancer journal	SA Scott, EM Marin, KT Maples, NS Joseph, CC Hofmeister, VA Gupta, MV Dhodapkar, JL Kaufman, S Lonial, AK Nooka	12/20/2023
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget	A Canella, HC Nieves, DW Sborov, L Cascione, HS Radomska, E Smith, A Stiff, J Consiglio, E Caserta, L Rizzotto, N Zanesi, V Stefano, B Kaur, X Mo, JC Byrd, YA Efebera, CC Hofmeister, F Pichiorri	09/25/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. Research square	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	09/21/2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO oncology practice	LF Sun, KT Maples, KH Hall, Y Liu, Y Cao, NS Joseph, CC Hofmeister, JL Kaufman, M Dhodapkar, AK Nooka, S Lonial, RD Harvey	09/01/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. bioRxiv : the preprint server for biology	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	08/22/2023
PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant. Haematologica	M Thomas, J Li, K King, AK Persaud, E Duah, Z Vangundy, CC Hofmeister, JK Lamba, AC Tan, BL Fridley, MJ Poi, ND Seligson	08/01/2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. The Journal of clinical investigation	MH Robinson, NY Villa, DL Jaye, AK Nooka, A Duffy, SS McCachren, J Manalo, JM Switchenko, S Barnes, S Potdar, MI Azeem, AA Horvat, VC Parihar, J Gong, Y Liang, GH Smith, VA Gupta, LH Boise, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar	08/01/2023
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood cancer discovery	MI Azeem, AK Nooka, U Shanmugasundaram, N Cheedarla, S Potdar, RJ Manalo, A Moreno, JM Switchenko, S Cheedarla, DB Doxie, R Radzievski, ML Ellis, KE Manning, B Wali, RM Valanparambil, KT Maples, E Baymon, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, JD Roback, A Sette, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar, KM Dhodapkar	03/01/2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. Blood cancer journal	KT Maples, KH Hall, NS Joseph, CC Hofmeister, V Gupta, MV Dhodapkar, JL Kaufman, AK Nooka, S Lonial	02/20/2023
Evaluating the Impacts of CYP3A41B and CYP3A53 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant. Cancer genomics & proteomics	J Li, YK Cho, DW Sborov, MA Phelps, CC Hofmeister, MJ Poi	01/01/2023
CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation. Frontiers in pharmacology	ND Seligson, X Zhang, MC Zemanek, JA Johnson, Z VanGundy, D Wang, MA Phelps, J Roddy, CC Hofmeister, J Li, MJ Poi	01/01/2023
Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia	M Slade, TG Martin, N Nathwani, MA Fiala, MP Rettig, F Gao, A Deol, FK Buadi, JL Kaufman, CC Hofmeister, TK Gregory, J Berdeja, A Chari, A Rosko, R Vij	12/01/2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, U Shanmugasundaram, N Cheedarla, H Verkerke, VV Edara, R Valanparambil, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, M Azeem, J Manalo, JM Switchenko, A Chang, SL Linderman, JD Roback, KM Dhodapkar, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar	09/10/2022
Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood cancer journal	VA Gupta, SM Matulis, BG Barwick, RD Bog, CW Shebelut, M Shanmugam, P Neri, NJ Bahlis, MV Dhodapkar, LT Heffner, CC Hofmeister, NS Joseph, S Lonial, JL Kaufman, DL Jaye, AK Nooka, LH Boise	08/04/2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy	A Sivakumar, EB Bryson, KH Hall, KT Maples, S Goyal, NS Joseph, CC Hofmeister, JL Kaufman, S Lonial, AK Nooka, RD Harvey	03/01/2022
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. American journal of hematology	RF Cornell, R Baz, JR Richter, A Rossi, DT Vogl, C Chen, C Shustik, MJ Alvarez, Y Shen, TJ Unger, O Ben-Shahar, H Wang, E Baloglu, W Senapedis, X Ma, Y Landesman, X Bai, J Bader, H Xu, T Marshall, H Chang, CJ Walker, J Shah, S Shacham, MG Kauffman, CC Hofmeister	02/01/2022
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and cellular therapy	NS Joseph, VA Gupta, S Wyman, M Graiser, JL Kaufman, D Almaula, J Andrews, C Hofmeister, M Dhodapkar, LT Heffner, S Lonial, AK Nooka	02/01/2022
A Single Nucleotide Polymorphism (SNP) in the SLC22A3 Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. Anticancer research	J Li, AK Persaud, JA Johnson, DW Sborov, MA Phelps, CC Hofmeister, MJ Poi	01/01/2022
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood cancer discovery	A Kaushal, AK Nooka, AR Carr, KE Pendleton, BG Barwick, J Manalo, SS McCachren, VA Gupta, NS Joseph, CC Hofmeister, JL Kaufman, LT Heffner, SM Ansell, LH Boise, S Lonial, KM Dhodapkar, MV Dhodapkar	11/01/2021
Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. European journal of drug metabolism and pharmacokinetics	S Liva, M Chen, A Mortazavi, A Walker, J Wang, K Dittmar, C Hofmeister, CC Coss, MA Phelps	11/01/2021
Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope investigative otolaryngology	DB Welling, KA Collier, SS Burns, JL Oblinger, E Shu, BA Miles-Markley, CC Hofmeister, MS Makary, HW Slone, JO Blakeley, SA Mansouri, BA Neff, RK Jackler, A Mortazavi, LS Chang	10/01/2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood	VA Gupta, BG Barwick, SM Matulis, R Shirasaki, DL Jaye, JJ Keats, B Oberlton, NS Joseph, CC Hofmeister, LT Heffner, MV Dhodapkar, AK Nooka, S Lonial, CS Mitsiades, JL Kaufman, LH Boise	07/01/2021
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	BG Barwick, VA Gupta, SM Matulis, JC Patton, DR Powell, Y Gu, DL Jaye, KN Conneely, YC Lin, CC Hofmeister, AK Nooka, JJ Keats, S Lonial, PM Vertino, LH Boise	06/01/2021
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer chemotherapy and pharmacology	KA Collier, H Valencia, H Newton, EM Hade, DW Sborov, R Cavaliere, M Poi, MA Phelps, SG Liva, CC Coss, J Wang, S Khountham, P Monk, CL Shapiro, R Piekarz, CC Hofmeister, DB Welling, A Mortazavi	05/01/2021
Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. Molecular therapy oncolytics	J Ghose, A Dona, M Murtadha, EG Gunes, E Caserta, JY Yoo, L Russell, AC Jaime-Ramirez, BG Barwick, VA Gupta, JF Sanchez, DW Sborov, ST Rosen, A Krishnan, LH Boise, B Kaur, CC Hofmeister, F Pichiorri	03/26/2021
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American journal of hematology	KT Maples, AK Nooka, V Gupta, NS Joseph, LT Heffner, C Hofmeister, M Dhodapkar, SM Matulis, S Lonial, LH Boise, JL Kaufman	03/01/2021
Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. Frontiers in immunology	P Shindiapina, M Pietrzak, M Seweryn, E McLaughlin, X Zhang, M Makowski, EH Ahmed, S Schlotter, R Pearson, R Kitzler, A Mozhenkova, J Le-Rademacher, RF Little, G Akpek, E Ayala, SM Devine, LD Kaplan, A Noy, UR Popat, JW Hsu, LE Morris, AM Mendizabal, A Krishnan, W Wachsman, N Williams, N Sharma, CC Hofmeister, SJ Forman, WH Navarro, JC Alvarnas, RF Ambinder, G Lozanski, RA Baiocchi	01/01/2021
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia	D Viola, A Dona, E Caserta, E Troadec, F Besi, T McDonald, L Ghoda, EG Gunes, JF Sanchez, J Khalife, M Martella, C Karanes, M Htut, X Wang, M Rosenzweig, A Chowdhury, D Sborov, RR Miles, PJ Yazaki, T Ebner, CC Hofmeister, SJ Forman, ST Rosen, G Marcucci, J Shively, JJ Keats, A Krishnan, F Pichiorri	01/01/2021
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood cancer journal	Y Gu, BG Barwick, M Shanmugam, CC Hofmeister, J Kaufman, A Nooka, V Gupta, M Dhodapkar, LH Boise, S Lonial	12/14/2020
Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. British journal of clinical pharmacology	K Sweiss, B Vemu, CC Hofmeister, E Wenzler, GS Calip, JP Galvin, N Mahmud, D Rondelli, JJ Johnson, P Patel	11/01/2020
Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. Anticancer research	J Li, N Seligson, X Zhang, J Johnson, Z Vangundy, D Wang, M Phelps, C Hofmeister, W Sadee, MJ Poi	10/01/2020
Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids. Clinical journal of oncology nursing	SM Belcher, D Watkins Bruner, CC Hofmeister, J Kweon, SH Meghani, KA Yeager	10/01/2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia	M Gavriatopoulou, A Chari, C Chen, N Bahlis, DT Vogl, A Jakubowiak, D Dingli, RF Cornell, CC Hofmeister, D Siegel, JG Berdeja, D Reece, D White, S Lentzsch, C Gasparetto, CA Huff, S Jagannath, R Baz, AK Nooka, J Richter, R Abonour, TL Parker, AJ Yee, P Moreau, S Lonial, S Tuchman, KC Weisel, M Mohty, S Choquet, TJ Unger, K Li, Y Chai, L Li, J Shah, S Shacham, MG Kauffman, MA Dimopoulos	09/01/2020
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia	CO Landgren, A Chari, YC Cohen, A Spencer, P Voorhees, JA Estell, I Sandhu, MW Jenner, C Williams, M Cavo, NWCJ van de Donk, M Beksac, P Moreau, H Goldschmidt, S Kuppens, R Bandekar, PL Clemens, T Neff, C Heuck, M Qi, CC Hofmeister	07/01/2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, LT Heffner, VA Gupta, LH Boise, S Lonial, AK Nooka	06/10/2020
Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	N Sharma, DT Chen, Q Zhao, NY Williams, A Rosko, DM Benson, M Chaudhry, N Bumma, A Khan, S Devarakonda, CC Hofmeister, D Sborov, YA Efebera	01/01/2020
XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. Molecular carcinogenesis	AK Persaud, J Li, JA Johnson, N Seligson, DW Sborov, E Duah, YK Cho, D Wang, MA Phelps, CC Hofmeister, MJ Poi	12/01/2019
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood cancer journal	TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, MV Dhodapkar, VA Gupta, DL Jaye, J Wu, S Goyal, Z Chen, LH Boise, S Lonial, AK Nooka, JL Kaufman	11/25/2019
MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI insight	J Khalife, J Ghose, M Martella, D Viola, A Rocci, E Troadec, C Terrazas, AR Satoskar, EG Gunes, A Dona, JF Sanchez, PL Bergsagel, M Chesi, A Pozhitkov, S Rosen, G Marcucci, JJ Keats, CC Hofmeister, A Krishnan, E Caserta, F Pichiorri	11/01/2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. Bone marrow transplantation	S Singer, N Sharma, R Dean, Q Zhao, D Abounader, P Elder, CC Hofmeister, DM Benson, A Rosko, S Penza, L Andritsos, S Vasu, S Jaglowski, BM William, B Bolwell, B Pohlman, M Kalaycio, D Jagadeesh, B Hill, R Sobecks, SM Devine, NS Majhail, YA Efebera	10/01/2019
Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. Leukemia research	LA Andritsos, Y Huang, I Abraham, K Huff, SR Scrape, T Fan, N Alkhatib, CC Hofmeister, E Drea, A McBride	10/01/2019
Daratumumab in multiple myeloma. Cancer	AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, HC Sullivan, AS Neish, MV Dhodapkar, S Lonial	07/15/2019
Registering a CD38 antibody upfront for multiple myeloma. Lancet (London, England)	CC Hofmeister, A Nooka, JL Kaufman, S Lonial	07/06/2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	S Singer, R Dean, Q Zhao, N Sharma, D Abounader, P Elder, CC Hofmeister, DM Benson, A Rosko, S Penza, L Andritsos, S Vasu, S Jaglowski, BM William, B Bolwell, B Pohlman, M Kalaycio, D Jagadeesh, B Hill, R Sobecks, SM Devine, NS Majhail, YA Efebera	06/01/2019
Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease? Bone marrow transplantation	JL Vaughn, Q Zhao, N Epperla, M Puto, J Roddy, P Elder, W Blum, R Klisovic, S Jaglowski, S Penza, B William, L Andritsos, JE Brammer, C Hofmeister, Y Efebera, D Benson, S Devine, S Cataland, S Vasu	06/01/2019
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. European journal of haematology	MA Dimopoulos, JP Laubach, MA Echeveste Gutierrez, N Grzasko, CC Hofmeister, JF San-Miguel, S Kumar, R Labotka, V Lu, D Berg, C Byrne, Z Teng, G Liu, H van de Velde, PG Richardson	06/01/2019
Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. British journal of clinical pharmacology	JH Hughes, MA Phelps, RN Upton, SE Reuter, Y Gao, JC Byrd, MR Grever, CC Hofmeister, G Marcucci, W Blum, KA Blum, DJR Foster	05/01/2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI insight	JK Bailur, SS McCachren, DB Doxie, M Shrestha, K Pendleton, AK Nooka, N Neparidze, TL Parker, N Bar, JL Kaufman, CC Hofmeister, LH Boise, S Lonial, ML Kemp, KM Dhodapkar, MV Dhodapkar	04/23/2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature communications	BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, CC Hofmeister, JL Kaufman, VA Gupta, D Auclair, JJ Keats, S Lonial, PM Vertino, LH Boise	04/23/2019
Most multiple myeloma patients have low testosterone. Leukemia & lymphoma	S John, N Sharma, DW Sborov, N Williams, D Jones, DM Benson, YA Efebera, AE Rosko, J Vincent, CC Hofmeister	03/01/2019
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer	R Mina, NS Joseph, JL Kaufman, VA Gupta, LT Heffner, CC Hofmeister, LH Boise, MV Dhodapkar, C Gleason, AK Nooka, S Lonial	02/01/2019
A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer research	MJ Poi, J Li, JA Johnson, YK Cho, DW Sborov, MA Phelps, CC Hofmeister	01/01/2019
Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT). Archives of hematology and blood diseases	A Pandit, L Wei, L Bustamante, P Elder, WBS Falk, M Sell, A Rosko, DM Benson, SM Devine, CC Hofmeister, YA Efebera	01/01/2019
Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. Bone marrow transplantation	DR Richardson, Y Huang, HL McGinty, P Elder, J Newlin, C Kirkendall, L Andritsos, D Benson, W Blum, Y Efebera, S Penza, C Hofmeister, S Jaglowski, R Klisovic, S Vasu, B William, S Devine, AE Rosko	11/01/2018
Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant. CPT: pharmacometrics & systems pharmacology	YK Cho, DJ Irby, J Li, DW Sborov, DR Mould, M Badawi, A Dauki, M Lamprecht, AE Rosko, S Fernandez, EM Hade, CC Hofmeister, M Poi, MA Phelps	11/01/2018
Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia	H Barr, J Dempsey, A Waller, Y Huang, N Williams, N Sharma, DM Benson, AE Rosko, YA Efebera, CC Hofmeister	11/01/2018
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. British journal of haematology	PG Richardson, CC Hofmeister, CA Rosenbaum, M Htut, DH Vesole, JG Berdeja, M Liedtke, A Chari, SD Smith, D Lebovic, N Raje, C Byrne, E Liao, N Gupta, AD Bacco, J Estevam, D Berg, R Baz	07/01/2018
Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology	J Ghose, D Viola, C Terrazas, E Caserta, E Troadec, J Khalife, EG Gunes, J Sanchez, T McDonald, G Marcucci, B Kaur, M Rosenzweig, J Keats, S Rosen, A Krishnan, AR Satoskar, CC Hofmeister, F Pichiorri	01/01/2018

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
5	One star One star One star One star One star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	02/28/2025	Great Doctor.
One star One star One star One star One star	02/24/2025	Very good.
One star One star One star One star One star	01/09/2025	Dr.Hofmeister is the best!]
One star One star One star One star Empty star	11/28/2024	Dr Hofmeister was SUPER BEST YOU HAVE
One star One star One star One star Empty star	11/22/2024	Everything was clear and loud that I could understand what he was saying. I love communicating like that and makes it very easy for me.
One star One star One star One star One star	11/21/2024	Dr. Hofmeister was so knowledgeable about my diagnosis. He throughly explained my previous laboratory studies and how he would do a comparison from his laboratory orders. He provided excellent care and I'm glad he excepted my case to prove continued treatment as needed.
One star One star One star One star One star	11/09/2024	This was my first visit with Dr. Hofmeister. He is patient, clear, and empathetic. I am very grateful to have him care for me.
One star One star One star One star One star	10/24/2024	Dr Hoffmeister always listens and discusses current successes and plan of care going forward
One star One star One star One star One star	10/17/2024	Good relationship with healthcare team
One star One star One star One star One star	09/26/2024	Well rounded explanation of my treatment options with many chances to ask questions.
One star One star One star One star One star	09/17/2024	Dr Craig answers all your questions, explains things in layman's terms. Takes the time to ensure you understand with follow-up. Don't want MM but glad Dr. Craig is my doctor.
One star One star One star One star One star	08/28/2024	The doctor introduced himself and asked me to call him by his first name. Extremely knowledgeable and explained everything in an understandable manner.
One star One star One star One star One star	08/15/2024	Very good
One star One star One star One star One star	08/11/2024	Dr. Hofmeister was superb.
One star One star One star One star One star	08/08/2024	Dr Hoffmeister made his concerns and plans for my care moving forward. Always thankful for his ability to include both my son and myself in decisions about scheduling tests and procedures
One star One star One star One star One star	07/30/2024	Dr. Hofmeister explains everything so thoroughly. He listens closely to my questions and answers them completely. He is warm, engaging and personable.
One star One star One star One star One star	07/30/2024	Dr. H provided the precise feedback that I was hoping for
One star One star One star One star One star	07/11/2024	I LOVE DR. HOFMEISTER!!! I would recommend him to everyone!!!! I LOVE MS CHASE TOO! His team is great too!!!!
One star One star One star One star One star	06/20/2024	Dr Hofmeister is terrific. A great patient advocate.
One star One star One star One star One star	05/15/2024	Loved it
One star One star One star One star One star	05/14/2024	Took time to explain everything and allowed for all my questions.
One star One star One star One star One star	05/09/2024	Great feedback and answered my questions.
One star One star One star One star One star	04/27/2024	Awesome doctor with extraordinary manner
One star One star One star One star One star	04/24/2024	The most informative visit I have been involved in.